-

09:47:07 AM

CPIX Stock News

CPIX - Cumberland Pharmaceuticals Inc.

05/23/23 9:00 AM

Nasdaq : CPIX

clinical triallow float

CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

Cumberland initiating Phase II FIGHTING FIBROSIS™ clinical trial,. Newest program in Cumberland's ifetroban pipeline. As a result, Cumberland will launch its FIGHTING FIBROSIS trial designed to enroll 128 patients in over 20 medical centers of excellence across the U.S..

RHEA-AI

neutral

05/15/23 9:00 AM

Nasdaq : CPIX

fda approvallow float

CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has approved expanded labeling for Caldolor ®, an intravenously delivered formulation of ibuprofen,...

RHEA-AI

neutral

05/09/23 4:05 PM

Nasdaq : CPIX

earningslow float

Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the Company's product portfolio of FDA-approved brands delivered combined revenues of $9.2 million during the first quarter of 2023. Net income for the period was $0.2 million, or $0.01 a share, resulting in adjusted earnings of...

RHEA-AI

neutral

05/02/23 4:05 PM

Nasdaq : CPIX

low float

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS

Cumberland Pharmaceuticals Inc., a specialty pharmaceuticals company, announced today that it will release the first quarter 2023 financial results and provide a company update after the market closes on Tuesday, May 9, 2023.. A conference call will be held on May 9 at 4:30 p.m. Eastern Time, to discuss the results.

RHEA-AI

neutral

03/07/23 4:23 PM

Nasdaq : CPIX

low float

CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR FULL YEAR 2022

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company today announced full year 2022 financial results and provided a Company update. As of December 31, 2022, the Company's total assets were $93 million, including $20 million in cash. "We were able to manage our business in 2022 to deliver significant revenue growth despite facing external...

RHEA-AI

positive

02/28/23 4:05 PM

Nasdaq : CPIX

earningslow float

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2022 FINANCIAL RESULTS

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2022 financial results and provide a company update after the market closes on Tuesday, March 7, 2023.A conference

RHEA-AI

neutral

11/08/22 4:05 PM

Nasdaq : CPIX

low float

Cumberland Pharmaceuticals Reports 41% Revenue Growth

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $11.4 million

RHEA-AI

positive

11/01/22 4:05 PM

Nasdaq : CPIX

earningslow float

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2022 financial results and provide a company update after the market closes on Tuesday, Nov. 8, 2022.A

RHEA-AI

neutral

11/01/22 9:20 AM

Nasdaq : CPIX

low float

CUMBERLAND PHARMACEUTICALS MOVES INTO NEW HEADQUARTERS AT BROADWEST

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), the largest, public biopharmaceutical company founded and headquartered in Tennessee, announced today that it has moved its headquarters to the Broadwest campus in the Vanderbilt /West End corridor of

RHEA-AI

very positive

08/09/22 4:05 PM

Nasdaq : CPIX

low float

Cumberland Pharmaceuticals Reports 14% Revenue Growth

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of

RHEA-AI

positive

CPIX Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.cumberlandpharma.com
Security nameCumberland Pharmaceuticals Inc.
Issue typecs
SectorManufacturing
Sic code2834
Employees85
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About Cumberland Pharmaceuticals Inc.

Cumberland Emerging Technologies, Inc.(www.cet-fund.com)is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN and WinHealth Pharma. The mission of CET is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace. CET helps manage the development and commercialization process for select projects and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center, located in Nashville, Tennessee, provides laboratory space, equipment and infrastructure to early-stage life sciences companies.